Last reviewed · How we verify
short-course chemotherapy
At a glance
| Generic name | short-course chemotherapy |
|---|---|
| Sponsor | Associazione Italiana per lo Studio del Pancreas |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer (PHASE2)
- Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy (PHASE2)
- SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases (PHASE2)
- SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC (NA)
- Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) (PHASE2)
- PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer (PHASE2)
- Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC (PHASE2)
- Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- short-course chemotherapy CI brief — competitive landscape report
- short-course chemotherapy updates RSS · CI watch RSS
- Associazione Italiana per lo Studio del Pancreas portfolio CI